Rapidly Progressing CD8-negative Hypopigmented Mycosis Fungoides in Adult Caucasian Male with Good Response to Mogamulizumab
DOI:
https://doi.org/10.2340/actadv.v105.43932Keywords:
cucutaneous T-cell lymphoma, mogamulizumab, mycosis fungoidesAbstract
Hypopigmented mycosis fungoides is a rare variant of mycosis fungoides often seen in younger patients and individuals with darker skin tones and is characterized by hypopigmented patches or plaques. The lesions are usually asymptomatic and respond well to topical treat-ment or phototherapy. This article presents a case of an adult Caucasian male with a rare variant of CD8-negativeh hypopigmented mycosis fungoides, with a rapid progression to erythrodermic lesions, failure of standard treatment, and a good response to mogamulizumab.
Downloads
References
Furlan FC, Sanches JA. Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology. An Bras Dermatol 2013; 88: 954. DOI: https://doi.org/10.1590/abd1806-4841.20132336
Qari MS, Li N, Demierre M-F. Hypopigmented mycosis fungoides: case reports and literature review. J Cutan Med Surg 2000; 4: 142–148. DOI: https://doi.org/10.1177/120347540000400306
Djawad K. Hypopigmented mycosis fungoides mimicking leprosy successfully treated with oral and topical corticosteroids: a new great imitator? Acta Dermatovenerol Alp Pannonica Adriat 2021; 30: 83–85. DOI: https://doi.org/10.15570/actaapa.2021.20
Ardigó M, Borroni G, Muscardin L, Kerl H, Cerroni L. Hypopigmented mycosis fungoides in Caucasian patients: a clinicopathologic study of 7 cases. J Am Acad Dermatol 2003; 49: 264–270. DOI: https://doi.org/10.1067/S0190-9622(03)00907-1
Rodney IJ, Kindred C, Angra K, Qutub ON, Villanueva AR, Halder RM. Hypopigmented mycosis fungoides: a retrospective
clinicohistopathologic study. J Eur Acad Dermatol Venereol 2017; 31: 808–814. DOI: https://doi.org/10.1111/jdv.13843
Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798–812. DOI: https://doi.org/10.1172/JCI24826
Shi HZ, Jiang YQ, Xu XL, Zhang W, Song H, Wang XP, et al. Hypopigmented mycosis fungoides: a clinicopathological review of 32 patients. Clin Cosmet Investig Dermatol 2022; 15: 1259–1264. DOI: https://doi.org/10.2147/CCID.S370741
Stone ML, Styles AR, Cockerell CJ, Pandya AG. Hypopigmented mycosis fungoides: a report of 7 cases and review of the literature. Cutis 2001; 67: 133–138.
Singh ZN, Tretiakova MS, Shea CR, Petronic-Rosic VM. Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Mod Pathol 2006; 19: 1255–1260. DOI: https://doi.org/10.1038/modpathol.3800644
Kitamura R, Tsukamoto K, Harada K, Shimizu A, Shimada S, Kobayashi T, et al. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol 2004; 202: 463–475. DOI: https://doi.org/10.1002/path.1538
El-Darouti MA, Marzouk SA, Azzam O, Fawzi MM, Abdel-Halim MR, Zayed AA, et al. Vitiligo vs. hypopigmented mycosis fungoides (histopathological and immunohistochemical study, univariate analysis). Eur J Dermatol 2006; 16: 17–22.
El Shabrawi-Caelen L, Cerroni L, Medeiros LJ, McCalmont TH. Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype. Am J Surg Pathol 2002; 26: 450–457. DOI: https://doi.org/10.1097/00000478-200204000-00006
Sigal M, Grossin M, Laroche L, Basset F, Aitken G, Haziza JL, et al. Hypopigmented mycosis fungoides. Clin Exp Dermatol 1987; 12: 453–454. DOI: https://doi.org/10.1111/j.1365-2230.1987.tb01948.x
Robert C, Moulonguet I, Baudot N, Flageul B, Dubertret L. Hypopigmented mycosis fungoides in a light-skinned woman [2]. Br J Dermatol 1998; 139: 341–343. DOI: https://doi.org/10.1046/j.1365-2133.1998.02379.x
Amichai B, Grunwald MH, Avinoach I, Halevy S. Hypopigmented mycosis fungoides in a white female. J Dermatol 1996; 23: 425–426. DOI: https://doi.org/10.1111/j.1346-8138.1996.tb04046.x
Ito A, Sugita K, Ikeda A, Yamamoto O. CD4/CD8 double-negative mycosis fungoides: a case report and literature review. Yonago Acta Med 2019; 62: 153–158. DOI: https://doi.org/10.33160/yam.2019.03.021
Kempf W, Kazakov DV, Cipolat C, Kutzner H, Roncador G, Tomasini D. CD4/CD8 double negative mycosis fungoides with PD-1 (CD279) expression: a disease of follicular helper T-cells? Am J Dermatopathol 2012; 34: 757–761. DOI: https://doi.org/10.1097/DAD.0b013e31825b26d1
Poteligeo. Product information. Available on Dec 8, 2025 https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_en.pdf
Fernández-Guarino M, Ortiz P, Gallardo F, Llamas-Velasco M. Clinical and real-world effectiveness of mogamulizumab: a narrative review. Int J Mol Sci 2024; 25: 2203. DOI: https://doi.org/10.3390/ijms25042203
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192–1204. DOI: https://doi.org/10.1016/S1470-2045(18)30379-6
Rao M, Young K, Jackson-Cowan L, Kourosh A, Theodosakis N. Post-inflammatory hypopigmentation: review of the etiology, clinical manifestations, and treatment options. J Clin Med 2023; 12: 1243. DOI: https://doi.org/10.3390/jcm12031243
Rao AG, Naresh M, Shreeja V, Vsvn S, Sindhuja B, Pranaya B. CD4/CD8 dual positive pityriasis lichenoides like mycosis fungoides presenting with both pityriasis lichenoid lesions and hypopigmented patches: a rare presentation. Indian J Dermatol 2022; 67: 441–444. DOI: https://doi.org/10.4103/ijd.ijd_279_22
Published
How to Cite
License
Copyright (c) 2025 Agnieszka Kimak-Pielas, Taduesz Robak, Marcin Braun, Agnieszka Żebrowska, Ewa Robak
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
